# Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome

> **NCT07328529** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Azevan Pharmaceuticals** · enrollment: 80 (estimated)

## Conditions studied

- Aggressive Behavior in Fragile X Syndome

## Interventions

- **DRUG:** SRX246
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07328529
- **Lead sponsor:** Azevan Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2027-03
- **Final completion:** 2028-03
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07328529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07328529, "Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07328529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*